One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

被引：11
|
作者：
Wang, Michael
Munoz, Javier
Goy, Andre H.
Locke, Frederick L.
Jacobson, Caron A.
Hill, Brian T.
Timmerman, John M.
Holmes, Houston
Jaglowski, Samantha
Flinn, Ian W.
McSweeney, Peter A.
Miklos, David B.
Pagel, John M.
Kersten, Marie Jose
Milpied, Noel
Fung, Henry C. H.
Topp, Max S.
Houot, Roch
Beitinjaneh, Amer
Peng, Weimin
Zheng, Lianqing
Rossi, John M.
Murugappan, Swaminathan
Kloos, Ioana
Reagan, Patrick M.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136382
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [21] Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Boissel, Nicolas
    Cassaday, Ryan D.
    Leguay, Thibaut
    Bishop, Michael R.
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha L.
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Park, Jae H.
    Subklewe, Marion
    Abedi, Mehrdad
    Minnema, Monique C.
    Wierda, William G.
    DeAngelo, Daniel J.
    Stiff, Patrick
    Jeyakumar, Deepa
    Dong, Jinghui
    Adhikary, Sabina
    Zhou, Lang
    Schuberth, Petra C.
    Faghmous, Imi
    Masouleh, Behzad Kharabi
    Houot, Roch
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [22] ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (RR) chronic lymph ocytic leukemia (CLL).
    Flinn, Ian
    Marris, Michael
    Wierda, William G.
    Coutre, Steven
    Pagel, John M.
    Byrd, John C.
    Goyal, Lovely
    Goodman, Krista
    Zheng, Yan
    Milletti, Francesca
    Murugappan, Swaminathan
    Brown, Jennifer R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [23] Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
    Bijal D. Shah
    Armin Ghobadi
    Olalekan O. Oluwole
    Aaron C. Logan
    Nicolas Boissel
    Ryan D. Cassaday
    Thibaut Leguay
    Michael R. Bishop
    Max S. Topp
    Dimitrios Tzachanis
    Kristen M. O’Dwyer
    Martha L. Arellano
    Yi Lin
    Maria R. Baer
    Gary J. Schiller
    Jae H. Park
    Marion Subklewe
    Mehrdad Abedi
    Monique C. Minnema
    William G. Wierda
    Daniel J. DeAngelo
    Patrick Stiff
    Deepa Jeyakumar
    Jinghui Dong
    Sabina Adhikary
    Lang Zhou
    Petra C. Schuberth
    Imi Faghmous
    Behzad Kharabi Masouleh
    Roch Houot
    Journal of Hematology & Oncology, 15
  • [24] PATIENT REPORTED OUTCOMES AMONG KTE-X19 CAR T TREATED PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA (R/R MCL)
    Kersten, Jose M.
    Munoz, J.
    Milpied, N.
    Maglinte, G.
    Crawford, S.
    Solem, C.
    Rao, A., V
    Wang, M.
    VALUE IN HEALTH, 2020, 23 : S479 - S479
  • [25] Kte-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study from the Descar-T Registry and Lysa Group
    Herbaux, Charles
    Bret, Caroline
    Di Blasi, Roberta
    Bachy, Emmanuel
    Beauvais, David
    Gat, Elodie
    Gastinne, Thomas
    Broussais, Florence
    Cartron, Guillaume
    Cuffel, Alexis
    Ysebaert, Loic
    Roussel, Mikael
    Bouabdallah, Krimo
    Guy, Julien
    Campidelli, Arnaud
    Van Laethem, Francois
    Casasnovas, Rene-Olivier
    Dulery, Remy
    Morschhauser, Franck
    Caillat-Zucman, Sophie
    Houot, Roch
    Le Gouill, Steven
    BLOOD, 2021, 138
  • [26] KTE-X19 in Relapsed or Refractory Mantle-Cell Lymphoma, a "Real-Life" Study From the DESCAR-T Registry and LYSA Group
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (02) : 15 - 16
  • [27] Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia
    Wayne, Alan S.
    Van Huynh, Van
    Hijiya, Nobuko
    Rouce, Rayne H.
    Brown, Patrick A.
    Krueger, Joerg
    Kitko, Carrie L.
    Dela Ziga, Edward
    Hermiston, Michelle L.
    Richards, Michael K.
    Baruchel, Andre
    Schuberth, Petra C.
    Rossi, John
    Zhou, Lang
    Goyal, Lovely
    Jain, Rajul
    Vezan, Remus
    Masouleh, Behzad Kharabi
    Lee, Daniel W.
    HAEMATOLOGICA, 2023, 108 (03) : 747 - 760
  • [28] ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
    Wang, M.
    Locke, F. L.
    Siddiqi, T.
    Castro, J.
    Shah, B.
    Lee, H.
    Budde, L. E.
    Choi, M.
    Anasetti, C.
    Champlin, R.
    Forman, S.
    Kipps, T.
    Bot, A.
    Rossi, J. M.
    Navale, L.
    Jiang, Y.
    Aycock, J.
    Elias, M.
    Wiezorek, J.
    Go, W. Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma (R/R MCL) in ZUMA-2: Durable responder analysis
    Munoz, Javier
    Reagan, Patrick M.
    Goy, Andre
    Miklos, David B.
    Zheng, Dan
    Fang, Xiang
    Shen, Rhine R.
    Siddiqi, Rubina
    Kloos, Ioana
    Kersten, Marie Jose
    Wang, Michael
    ANNALS OF ONCOLOGY, 2023, 34 : S1380 - S1380
  • [30] 2-year update of KTE-X19 in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3
    Shah, Bijal D.
    Ghobadi, Armin
    Oluwole, Olalekan O.
    Logan, Aaron C.
    Boissel, Nicolas
    Cassaday, Ryan D.
    Forcade, Edouard
    Bishop, Michael R.
    Topp, Max S.
    Tzachanis, Dimitrios
    O'Dwyer, Kristen M.
    Arellano, Martha L.
    Lin, Yi
    Baer, Maria R.
    Schiller, Gary J.
    Zhou, Lang
    Schuberth, Petra C.
    Masouleh, Behzad Kharabi
    Houot, Roch
    ANNALS OF ONCOLOGY, 2023, 34 : S1389 - S1389
12345